Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition.

[1]  F. Duprat,et al.  Sensing pressure in the cardiovascular system: Gq-coupled mechanoreceptors and TRP channels. , 2010, Journal of molecular and cellular cardiology.

[2]  J. Hell,et al.  Physical and Functional Interaction Between Calcineurin and the Cardiac L-Type Ca2+ Channel , 2009, Circulation research.

[3]  Muzamil M. Z. Noorani,et al.  Inhibition of TRPC1/TRPC3 by PKG contributes to NO-mediated vasorelaxation. , 2009, American journal of physiology. Heart and circulatory physiology.

[4]  E. Schroder,et al.  L-Type Calcium Channel C Terminus Autoregulates Transcription , 2009, Circulation research.

[5]  D. Kass,et al.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. , 2009, Pharmacology & therapeutics.

[6]  H. Ghofrani,et al.  A Functional Single-Nucleotide Polymorphism in the TRPC6 Gene Promoter Associated With Idiopathic Pulmonary Arterial Hypertension , 2009, Circulation.

[7]  Brian O'Rourke,et al.  Electrophysiological Consequences of Dyssynchronous Heart Failure and Its Restoration by Resynchronization Therapy , 2009, Circulation.

[8]  D. Kass,et al.  Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. , 2009, Journal of the American College of Cardiology.

[9]  D. Kass,et al.  Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. , 2008, Cardiovascular research.

[10]  D. Kass,et al.  Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. , 2008, Cellular signalling.

[11]  Y. Mori,et al.  Nitric oxide–cGMP–protein kinase G pathway negatively regulates vascular transient receptor potential channel TRPC6 , 2008, The Journal of physiology.

[12]  J. O-Uchi,et al.  Interaction of &agr;1-Adrenoceptor Subtypes With Different G Proteins Induces Opposite Effects on Cardiac L-type Ca2+ Channel , 2008, Circulation research.

[13]  H. Brinkmeier,et al.  Transient receptor potential cation channels in normal and dystrophic mdx muscle , 2008, Neuromuscular Disorders.

[14]  C. Des Rosiers,et al.  Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency , 2008, Proceedings of the National Academy of Sciences.

[15]  David A. Kass,et al.  Tackling heart failure in the twenty-first century , 2008, Nature.

[16]  D. Kass,et al.  Phosphodiesterase type 5: expanding roles in cardiovascular regulation. , 2007, Circulation research.

[17]  J. Lowe,et al.  Selective Activation of Human Atrial Gα12 and Gα13 by Gαq-coupled Angiotensin and Endothelin Receptors , 2007 .

[18]  M. Mongillo,et al.  Protein Kinase G Phosphorylates Cav1.2 α1c and β2 Subunits , 2007, Circulation research.

[19]  C. Montell,et al.  Integration of phosphoinositide- and calmodulin-mediated regulation of TRPC6. , 2007, Molecular cell.

[20]  T. O’Connell,et al.  Isolation and culture of adult mouse cardiac myocytes. , 2007, Methods in molecular biology.

[21]  J. Lowe,et al.  Selective activation of human atrial Galpha12 and Galpha13 by Galphaq-coupled angiotensin and endothelin receptors. , 2007, Journal of cardiovascular pharmacology.

[22]  J. A. Peters,et al.  Transient receptor potential cation channels in disease. , 2007, Physiological reviews.

[23]  John McAnally,et al.  TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. , 2006, The Journal of clinical investigation.

[24]  M. Nishida,et al.  TRPC3 and TRPC6 are essential for angiotensin II‐induced cardiac hypertrophy , 2006, The EMBO journal.

[25]  E. Olson,et al.  Canonical Transient Receptor Potential Channels Promote Cardiomyocyte Hypertrophy through Activation of Calcineurin Signaling* , 2006, Journal of Biological Chemistry.

[26]  Y. Hara,et al.  TRP Channels: Molecular Diversity and Physiological Function , 2006, Microcirculation.

[27]  D. Castrillon,et al.  Foxo Transcription Factors Blunt Cardiac Hypertrophy by Inhibiting Calcineurin Signaling , 2006, Circulation.

[28]  H. Nakayama,et al.  Calcineurin‐dependent cardiomyopathy is activated by TRPC in the adult mouse heart , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  M. Nishida,et al.  Transient Receptor Potential Channels in Cardiovascular Function and Disease , 2006, Circulation research.

[30]  M. Pericak-Vance,et al.  A Mutation in the TRPC6 Cation Channel Causes Familial Focal Segmental Glomerulosclerosis , 2005, Science.

[31]  Bernd Zetsche,et al.  Local Atrial Natriuretic Peptide Signaling Prevents Hypertensive Cardiac Hypertrophy in Endothelial Nitric-oxide Synthase-deficient Mice* , 2005, Journal of Biological Chemistry.

[32]  N. Koitabashi,et al.  Carvedilol effectively blocks oxidative stress-mediated downregulation of sarcoplasmic reticulum Ca2+-ATPase 2 gene transcription through modification of Sp1 binding. , 2005, Biochemical and biophysical research communications.

[33]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[34]  Da-Zhi Wang,et al.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. , 2004, The Journal of clinical investigation.

[35]  H. Kwan,et al.  Regulation of canonical transient receptor potential isoform 3 (TRPC3) channel by protein kinase G. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Lin Chen,et al.  Transcriptional regulation by calcium, calcineurin, and NFAT. , 2003, Genes & development.

[37]  H. Drexler,et al.  Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Weiss,et al.  Targeted Inhibition of Calcineurin in Pressure-overload Cardiac Hypertrophy , 2002, The Journal of Biological Chemistry.

[39]  J. Molkentin,et al.  Impaired cardiac hypertrophic response in Calcineurin Aβ-deficient mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Y. Hara,et al.  The Transient Receptor Potential Protein Homologue TRP6 Is the Essential Component of Vascular &agr;1-Adrenoceptor–Activated Ca2+-Permeable Cation Channel , 2001, Circulation research.

[41]  M. S. Taylor,et al.  Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Pignier,et al.  Characterization of nifedipine-resistant calcium current in neonatal rat ventricular cardiomyocytes. , 2000, American journal of physiology. Heart and circulatory physiology.

[43]  A. Fukamizu,et al.  Expression and characterization of mouse angiotensin II type 1a receptor tagging hemagglutinin epitope in cultured cells. , 1999, International journal of molecular medicine.

[44]  T. Gudermann,et al.  Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol , 1999, Nature.

[45]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[46]  N. Takahashi,et al.  Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. , 1998, The Journal of clinical investigation.

[47]  D. Glass,et al.  Phosphorylation by cyclic GMP-dependent protein kinase of a synthetic peptide corresponding to the autophosphorylation site in the enzyme. , 1983, The Journal of biological chemistry.